Live Breaking News & Updates on டேவிட் பிரதான

Stay updated with breaking news from டேவிட் பிரதான. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences


Share this article
Share this article
VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/  Notch Therapeutics Inc., a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond, Ph.D. as Senior Vice President, Preclinical and Translational Sciences. Dr. Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering.
We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND, said David Main, President and Chief Executive Officer of Notch. Adding Chris to our leadership team will bolster our preclinical pipeline and translational research capabilities to accelerate development of the company s cell therapy candidates from discovery into clinical applicatio ....

British Columbia , Chris Bond , Mary Moynihan , Peter Zandstra , Sunnybrook Research Institute , Centre For Commercialization Of Regenerative Medicine , Translational Sciences , University Of Toronto , Oncomed Pharmaceuticals , University Of Washington , Notch Therapeutics Inc , Preclinical Translational Sciences , Senior Vice President , Vice President , David Main , Chief Executive Officer , Juno Therapeutics , Editas Medicine , Notch Therapeutics , Engineered Thymic Niche , Toronto Innovation Acceleration Partners , Regenerative Medicine , பிரிட்டிஷ் கொலம்பியா , கிறிஸ் பத்திரம் , மேரி மாய்நீஹாந் , சன்னிபிரூக் ஆராய்ச்சி நிறுவனம் ,